Prevalence of Non-AIDS Comorbidities and Factors Associated with Metabolic Complications among HIV-Infected Patients at a Thai Referral Hospital

Chotirat Nakaranurack, BCP1, and Weerawat Manosuthi, MD2

Abstract

Objectives: The prevalence of non-AIDS-related comorbidities is increasing in HIV-infected patients receiving antiretroviral therapy. In Thailand, data regarding the prevalence of non-AIDS comorbidities and factors associated with metabolic complications in HIV-infected patients have not been well-documented. Methods: This cross-sectional study was conducted in 2011 and included 874 HIV-infected patients. Results: The age of patients was 45(8) years represented as mean (standard deviation [SD]). The current CD4 count was 502(247) cells/mm3. In all, 388 (44%) of the included patients had at least 1 non-AIDS comorbidity. The most frequently documented comorbidities were hyperlipidemia in 271 (70%) patients. Using multivariate analysis, older age (odds ratio [OR] = 1.82, 95% confidence interval [CI] = 1.51-2.19), male sex (OR = 1.55, 95%CI = 1.14-2.11), high current CD4 count (OR = 1.00, 95%CI = 1.00-1.00), and taking abacavir (ABC)-containing (OR = 2.59, 95%CI = 1.16-5.78) and didanosine (ddI)-containing antiretroviral regimens (OR = 4.16, 95%CI = 1.09-15.84) were associated with the presence of metabolic complications (all Ps<.05). Conclusion: The prevalence of comorbidities is substantially high. Clinical monitoring and effective management of these comorbidities and metabolic complications are recommended, especially in HIV-infected patients who present with these associated factors.

Keywords
HIV, comorbidities, factors, metabolic complications, Thailand

Introduction

In 2013, the reported prevalence of HIV-infected patients in the adult Thai population was 1.1%.1 Currently, HIV infection is a chronic but manageable disease. All HIV-infected patients require long-term effective antiretroviral treatment. Thailand is a middle-income country that produces affordable generic antiretroviral drugs. Most patients, therefore, have access to antiretroviral therapies.2 Such patients not only live longer but also experience long-term toxicities that result from antiretroviral drugs along with HIV-related comorbidities.3,4

The existing literature shows that non-AIDS-related comorbidities are increasing. These include cardiovascular disease, metabolic syndrome, renal and bone diseases, cancer, and neurocognitive impairment.5,6 Such comorbidities are more prevalent among HIV-infected patients compared to the general population.5,4 In developing countries, a systematic review of the epidemiology of comorbidities in HIV/AIDS and noncommunicable diseases found that more than one-third of HIV-infected patients had an underlying cardiovascular disorder. The reported prevalence of metabolic syndrome ranges from 11% to 28% in HIV-infected patients.7 In addition, some studies have reported a slightly increased prevalence of metabolic syndrome.1,9 Age is one of the major risk factors for non-AIDS-related comorbidities. Other risk factors include a low immune status, the duration of antiretroviral drug exposure, the use of injected drugs, male gender, and specific drug regimens.5,6,9,10 This is a cross-sectional study with the objective of describing (1) the prevalence of non-AIDS comorbidities and (2) the factors associated with metabolic complications among Thai HIV-infected patients.

1 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
2 Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand

Corresponding Author:
Weerawat Manosuthi, Department of Medicine, Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thiwanon Road, Nonthaburi 11000, Thailand.
Email: drweerawat@hotmail.com
Methods

Selection and Description of Participants

A cross-sectional study was conducted at the Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand. This institute is a 300-bed tertiary HIV referral center located directly northwest of Bangkok. The institutional ethics committee of the Bamrasnaradura Infectious Disease Institute reviewed and approved the study. Inclusion criteria were as follows: (1) HIV-infected patients who were aged 18 years or older and (2) HIV-infected patients who had received HIV care at the Bamrasnaradura Infectious Disease Institute in 2011.

Data Collection

All patients’ identification numbers were obtained from the annual database of the institute. The data were extracted from medical records. International Classification of Diseases, Tenth Revision (ICD-10) diagnostic code was used to identify comorbid conditions in the Bamrasnaradura Infectious Disease Institute electronic database. All data were retrieved, including baseline demographics, clinical characteristics, and antiretroviral drug regimens. The metabolic comorbidities in the study included hyperlipidemia, hypertension, diabetes mellitus, and impaired fasting glucose. Viral hepatitis coinfections included hepatitis B and hepatitis C. Neurological diseases included stroke, Parkinson disease, epilepsy, and

| Characteristics | Total (N = 874) | With Comorbidity (n = 388) | Without Comorbidity (n = 486) | P Value |
|-----------------|----------------|---------------------------|-----------------------------|--------|
| Male sex, %     | 502 (57%)      | 247 (64%)                 | 255 (53%)                   | .001   |
| Age, mean (SD), years | 45.5 (8.3)   | 47.7 (9.2)                | 43.8 (6.9)                  | <.001  |
| Plasma HIV-RNA level <40 copies/mL, % | 853 (97%) | 376 (97%) | 477 (98%) | .692 |
| CD4 count, mean (SD), cells/mm³ | 502 (247) | 523 (245) | 485 (245) | .020 |
| Duration of receiving antiretroviral therapy, mean (SD), years | 8.4 (2.3) | 8.5 (2.3) | 8.2 (2.3) | .008 |
| Receiving nonnucleoside reverse transcriptase inhibitor(%) | 420 (63%) | 158 (56%) | 262 (68%) | .038 |
| NVP             | 420 (63%)      | 158 (56%)                 | 262 (68%)                   | <.001  |
| EFV             | 247 (37%)      | 123 (44%)                 | 124 (32%)                   | .038   |
| Receiving protease inhibitors, % | 104 (12%) | 44 (11%) | 60 (12%) | .640 |
| LPV/r           | 75 (7%)        | 30 (68%)                  | 45 (74%)                    | .481   |
| ATV/r           | 16 (15%)       | 8 (18%)                   | 8 (13%)                     | .652   |
| Darunavir/r     | 13 (13%)       | 6 (14%)                   | 7 (13%)                     | .901   |
| Receiving nucleoside/nucleotide reverse transcriptase inhibitors, % | | | | |
| TDF/3TC         | 415 (48%)      | 179 (46%)                 | 236 (49%)                   | .484   |
| ZDV/3TC         | 280 (32.2%)    | 98 (25%)                  | 182 (37%)                   | <.001  |
| ABC/3TC         | 42 (5%)        | 31 (8%)                   | 11 (2%)                     | <.001  |
| d4T/3TC         | 36 (4%)        | 17 (4%)                   | 19 (4%)                     | .732   |
| Receiving other regimens, % | 101 (12%) | 63 (16%) | 38 (8%) | <.001 |
| 3TC/LPV/r       | 29 (29%)       | 19 (30%)                  | 10 (26%)                    | .63    |
| Protease inhibitors monotherapy | 24 (24%) | 13 (20%) | 11 (29%) | .226 |
| ddI based       | 19 (19%)       | 15 (24%)                  | 4 (11%)                     | .254   |
| Nucleoside/nucleotide reverse transcriptase inhibitors not coadministered with 3TC | 13 (13%) | 4 (6%) | 9 (24%) | .901 |
| Protease inhibitor/nonnucleoside reverse transcriptase inhibitor | 12 (12%) | 9 (14%) | 3 (8%) | .330 |
| Integrase inhibitors | 2 (2%) | 1 (2%) | 1 (3%) | .874 |
| Double-boosted protease inhibitors | 2 (2%) | 2 (3%) | 0 (0%) | .874 |

Antiretroviral drugs, number (%)

| Antiretroviral drugs | Total (N = 874) | With Comorbidity (n = 388) | Without Comorbidity (n = 486) | P Value |
|----------------------|----------------|---------------------------|-----------------------------|--------|
| TDF                  | 421 (48%)      | 180 (46%)                 | 241 (49%)                   | .354   |
| ZDV                  | 293 (33%)      | 107 (27%)                 | 186 (38%)                   | <.001  |
| d4T                  | 37 (4%)        | 17 (4%)                   | 20 (4%)                     | .851   |
| ABC                  | 47 (5%)        | 35 (9%)                   | 12 (2%)                     | <.001  |
| ddI                  | 19 (2%)        | 15 (4%)                   | 4 (0.6%)                    | .002   |
| EFV                  | 259 (29%)      | 130 (33%)                 | 129 (26%)                   | .026   |
| NVP                  | 425 (49%)      | 163 (42%)                 | 262 (54%)                   | <.001  |
| LPV/r               | 138 (16%)      | 64 (16%)                 | 74 (15%)                     | .619   |
| ATV                  | 26 (3%)        | 15 (4%)                   | 11 (2%)                     | .168   |
| Darunavir            | 21 (2%)        | 13 (3%)                   | 8 (2%)                      | .103   |

Abbreviations: ABC, abacavir; ATV, atazanavir; ddI, didanosine; EFV, efavirenz; 3TC, lamivudine; NVP, nevirapine; LPV/r, lopinavir/ritonavir; SD, standard deviation; d4t, stavudine; TDF, tenofovir; ZDV, zidovudine.

Table 1. Baseline Characteristics of 874 HIV-Infected Patients.
dementia. Cardiovascular diseases included congestive heart failure, myocardial infarction, and cardiomyopathy. Thyroid diseases included hyperthyroid, hypothyroid, thyrotoxicosis, and nontoxic thyroid nodules.

**Statistical Analysis**

Means (standard deviation, SD) and frequencies (%) were used to describe patients’ baseline characteristics and the prevalence of comorbidities. Gender, antiretroviral drug regimens, and comorbidities were classified as categorical variables. Age, CD4 counts, plasma HIV-RNA levels, and the duration of receiving antiretroviral drugs were treated as continuous variables. Logistic regression was used to assess the association between metabolic complications and interesting potential variables. The odds ratio (OR) and its 95% confidence interval were estimated. In this study, the logistic regression analyses showed that data using “antiretroviral drug regimen” and “each antiretroviral drug” were independent variables. In univariate analyses, any variables with a P value <.1 were included in the multivariate analyses. Variables were found to be significant at P value < 0.05. All analyses were performed using SPSS version 15.0.

**Results**

The study involved 874 patients. The mean age of the patients was 45(8) years, and 502 (57%) participants were male. CD4 counts were 502(247) cells/mm³, and 853 (97%) of the patients had plasma HIV-RNA levels <40 copies/mL. Patients’ baseline characteristics are summarized in Table 1. Of the 874 patients, 388 (44%) had comorbidities. The number of comorbidities and the number of comorbidities stratified by age are shown in Figure 1A and B, respectively. Of all the patients, 347 (89%) had metabolic complications, including hyperlipidemia in 271 (70%) patients, hypertension in 106 (27%) patients, diabetes mellitus in 93 (24%) patients, and impaired fasting glucose in 31 (8.0%) patients. The prevalence of each individual comorbidity is presented in Table 2.

The multivariate analyses of factors associated with metabolic complications are shown in Tables 3 and 4. The analyses showed that abacavir (ABC)/lamivudine (3TC)-containing regimens (OR = 3.05), age (increasing in 10-year intervals; OR = 1.84), male gender (OR = 1.53), and current CD4 count (OR = 1.00) were associated with an increase in the metabolic complications in HIV-infected patients. Nevirapine (NVP; OR = 0.67)-containing regimens were found to provide a protective effect. For individual antiretroviral drugs, the analysis showed that didanosine(ddI; OR = 4.16), ABC(OR = 2.59), male gender (OR = 1.55), age (increasing in 10-year intervals; OR = 1.82), and current CD4 count (OR = 1.00) were associated with increasing metabolic complications.

**Discussion**

The present study demonstrates that almost half of the HIV-infected patients had at least 1 comorbidity. The same trend was found in a retrospective study conducted in 2007 to 2008 in Nigeria, which showed that 36% of HIV-infected patients had at least 1 comorbidity.¹¹ This figure is considered to be high; therefore, medical management of HIV that addresses comorbidities is necessary. The most prevalent comorbidities in this
study were metabolic complications, including hyperlipidemia, hypertension, and diabetes mellitus. This finding corresponds to the findings of a previous cross-sectional study, which showed a high prevalence for hyperlipidemia among Thai HIV-infected patients. 

Hypertension and hyperlipidemia have also been documented as common comorbidities in Asian and Caucasian populations. Between 2000 and 2012, a systematic review of the epidemiology of comorbidities in developing countries found that cardiovascular diseases accounted for more than one-third of HIV-infected patients. However, the prevalence of diabetes mellitus was low compared to the results of the current study.

Two cross-sectional studies in Brazil and Canada found that mental health problems had the highest comorbidity prevalence. Underestimation may be an explanation as to why our study showed a low prevalence of neurocognitive impairments and mental health problems.

In terms of associated factors, this study shows that every 10-year increase in age was associated with a 1.8-fold risk of having metabolic complications. Older adults had a higher chance of having comorbidities compared to younger adults, which is consistent with other studies. A study in the United States showed that male gender was a risk factor for metabolic complications. Protease inhibitor-containing regimens were a risk factor for comorbidities in previous studies in the United States and the Netherlands. Antiretroviral drugs have both positive and negative effects, and they are associated with an increased risk of metabolic complications such as cardiovascular disease, insulin resistance, and dyslipidemia. A meta-analysis showed that specific

| Parameters                        | Univariate Analysis | Multivariate Analysis |
|-----------------------------------|---------------------|-----------------------|
|                                   | OR  | 95%CI   | P Value | OR  | 95%CI   | P Value |
| Age (increase every 10 years)     | 1.88 | 1.59-2.24 | <.001   | 1.84 | 1.53-2.22 | <.001   |
| Male gender                       | 1.53 | 1.16-2.03 | .003    | 1.53 | 1.13-2.07 | .006    |
| Current CD4 count                 | 1.00 | 1.00-1.00 | .019    | 1.00 | 1.00-1.00 | .026    |
| Duration of receiving ART         | 1.07 | 1.01-1.14 | .023    | 1.02 | 0.96-1.09 | .496    |
| ZDV/3TC containing regimen        | 0.72 | 0.54-0.97 | .033    | 0.88 | 0.64-1.22 | .453    |
| ABC/3TC containing regimen        | 4.05 | 2.04-8.02 | <.001   | 3.05 | 1.43-6.51 | .004    |
| NVP containing regimen            | 0.60 | 0.45-0.79 | <.001   | 0.67 | 0.50-0.91 | .010    |

Abbreviations: ABC, abacavir; ART, antiretroviral therapy; CI, confidence interval; 3TC, lamivudine; NVP, nevirapine; OR, odds ratio; ZDV, zidovudine.

4 Journal of the International Association of Providers of AIDS Care
protease inhibitors and ABC were associated with myocardial infarction.\textsuperscript{8,19} Using ddI, stavudine (d4T), efavirenz (EFV), lopinavir/ritonavir(LPV/r), or zidovudine (ZDV) were associated with dyslipidemia and diabetes mellitus.\textsuperscript{8} Both ABC and ddI were, in our study, associated with metabolic complications. Our study showed no association between using protease inhibitors and metabolic complications. This finding may be explained by the low number of patients in the study who received protease inhibitors. One explanation for ABC being a risk factor for metabolic complications but not myocardial infarction is that physicians might choose ABC for patients with chronic diseases prior to administering antiretroviral drugs. The NVP is well tolerated, and this study also found that NVP provides a protective effect.

The prevalence of dyslipidemia in Thailand was studied in 2009, and 47\%, 38\%, and 29\% of the patients had low high-density lipoprotein cholesterol, high triglycerides, or high low-density lipoprotein cholesterol, respectively.\textsuperscript{20} The prevalence of diabetes mellitus and hypertension were approximately 9.6\% and 22\%, respectively, in 2003 and 2004.\textsuperscript{21,22} This study showed a higher prevalence of dyslipidemia, diabetes mellitus, and hypertension in HIV-infected patients than in the general population. The same trend was found in the cross-sectional studies in Canada and the Netherlands, showing that HIV-infected patients displayed a higher prevalence of comorbidities than the general population.\textsuperscript{5,6} The reason for this may be that HIV-infected patients express higher levels of markers of systemic inflammation and coagulation than the general population, and this may be a side effect of antiretroviral drug use.\textsuperscript{5}

There are several limitations in our study. First, uninfected HIV patients were not used for comparison. Second, data for some associated factors, such as smoking, BMI, and illegal drug use, were not available. Third, some laboratory measurements were also missing, such as lipid parameters and fasting blood glucose. Fourth, we retrieved the data for ICD-10 diagnostic codes from a hospital database. Thus, some patients in our study were not screened for each comorbidity, and some comorbidities were not recorded with an ICD-10 diagnostic code.

The prevalence of non-AIDS comorbidities, particularly metabolic complications, is high in a middle-income country. Therefore, a comprehensive approach to managing such complications should be used when treating HIV-infected patients to achieve long-term survival.

Acknowledgments
The authors would like to thank the staff of the Bamrasnaradura Infectious Diseases Institute for their cooperation in data collection.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. HIV and AIDS Estimates.2013.http://www.unaids.org/en/regionscountries/countries/thailand/. Accessed October 3, 2014.
2. HIV and AIDS in Thailand.http://www.avert.org/hiv-aids-thailand.htm. Accessed October 3, 2014.
3. Peters B, Post F, Wierzbick AS, et al.Screening for chronic comorbid disease in people with HIV: the need for a strategic approach. \textit{HIV Med}. 2013;14(suppl 1):1–11.
4. Max B, Sherer R. Management of the adverse effect of antiretroviral therapy and medicationadherence. \textit{Clin Infect Dis}. 2000;30(suppl 2):96–116.
5. Schouten J, Wit FW, Stolte IG, et al; AGEhIV Cohort Study Group.Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. \textit{Clin Infect Dis}. 2014;59(12):1–29.
6. Kendall CE, Wong J, Taljaard M, et al.A cross-sectional, population-base study measuring comorbidity among people living with HIV in Ontario. \textit{BMC Public Health}. 2014;14:161.
7. Haregu TN, Oldenburg B, Setswe G, et al. Epidemiology of comorbidity of HIV/AIDS and non-communicable disease in developing countries: a systematic review. \textit{JGlobal Health Care Syst.} 2012;2(1):1–12.
8. Paula AA, Falcao MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanism and epidemiological aspects. \textit{AIDS Res Ther}. 2013;32:1–8.
9. Negin J, Martiniuk A, Cumming RG, et al.Prevalence of HIV and chronic comorbidities among older adults. \textit{AIDS}.2012;26(suppl 1):S55–S63.
10. Wu PY, Chen MY, Hsieh SM, et al.Comorbidities among the HIV-infected patients aged 40 years or older in Taiwan. \textit{PLoS One}. 2014;9(8):1–8.
11. Denue BA, Gashau W, Ekong E, et al.Prevalence of non HIV related co-morbidity in HIVpatients on highactive anti retroviraltherapy (HAART): a retrospective study. \textit{Ann Biol Res}. 2012;3(7):3333–3339.
12. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receivingantiretroviral therapy. \textit{J Med Assoc Thai}. 2007;90(3):452–458.
13. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn PA. Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY. \textit{J Urban Health}. 2011;88(3):507–516.
14. Hasse B, Ledergerber B, Furrer H, et al.Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. \textit{Clin Infect Dis}. 2011;53(11):1130–1139.
15. Metallidis S, Tsachouridou O, Skoura L, et al. Older HIV-infected patients—an underestimated population in northern Greece: epidemiology, risk of disease progression and death. \textit{Int J Infect Dis}. 2013;17(10):883–891.
16. Lo YC, Chen MY, Sheng WH, et alRisk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. \textit{HIV Med}. 2009;10(5):302–309.
17. Pumpradit W, Ananworanich J, Lolak S, et al.Neurocognitive impairment and psychiatric comorbidity in well-controlled
human immunodeficiency virus-infected Thais from the 2NN cohort study. J Neurovirol. 2010;16(1):76–82.
18. Silva T, Wagner S, Cardoso W, et al. Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Braz J Infect Dis. 2013;17(3):324–331.
19. Holodniy M, Hou N, Owens DK, et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8(3):e0059551.
20. Aekplakorn W, Taneepanichskul S, Kessomboon P, et al. Prevalence of dyslipidemia and management in the Thai population, National Health Examination Survey iv, 2009. J Lipids. 2014;2014:249584.
21. Aekplakorn W, Stolk RP, Neal B, et al. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care. 2003;26(10):2758–2763.
22. Aekplakorn W, Abbott-Klaffer J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the third national health examination survey, 2004. J Hypertens. 2008;26(10):191–198.